Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377019728> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4377019728 endingPage "D187" @default.
- W4377019728 startingPage "D186" @default.
- W4377019728 abstract "Abstract Objective To evaluate the specific effects of alirocumab and evolocumab on major cardiovascular events (MACE) and lipid profile in patients with diabetes. Methods We conducted a systematic review of literature according to the PRISMA statement. A total of 8 randomized control trials (RCTs) enrolling 20651 patients with diabetes were included. Mean follow–up was 51 weeks. We included RCTs which had compared the PCSK9i alirocumab and evolocumab with placebo in subjects with hypercholesterolemia and diabetes mellitus. Results MACE occurred in 8.7% of patients with diabetes randomized to PCSK9i vs. 11.0% of those randomized to placebo. Thus, the use of alirocumab or evolocumab reduced MACE by 18% (relative risk [RR] 0.82, 95% confidence interval [CI] 0.74–0.90), without differences between PCSK9i compounds (p= 0.70, I2 0.0%). Compared to control group, the use of PCSK9 inhibitors was associated with a significant % change from baseline in LDL–C (mean difference [MD]–58.48%; 95% CI: –63.73 to –53.22%), p<0.0001), HDL–C (MD5.21%; 95% CI: 3.26 to 7.17 %), triglycerides (MD–14.59%; 95% CI: –19.42 to –9.76%), non–HDL–C (MD –48.84%; 95% CI: –54.54 to –43.14%) and total cholesterol (MD–33.76%; 95% CI: –38.71 to –28.8%). A significant reduction of Lp(a) (MD–32.90%; 95% CI: –38.55 to –27.24%) were observed in PCSK9i group compared to placebo. Moreover, while LDL–C reduction was similar in both subgroups (Evolocumab: MD –63,3%; 95% CI: –74.87 to –51.72%, p<0.0001; alirocumab: MD –55.58%; 95% CI: –61.49 to –49.67%, p<0.0001; Test for subgroup differences: P= 0.24; I226.2%), the percentage of Lp(a) reduction was higher in evolocumab subgroup compared to alirocumab (MD –46.68 %; 95% CI: –60.73 to –32.63%, p<0.0001 vs –22.92 %; 95% CI: –28.58 to –17.25%, p<0.0001, respectively; Test for subgroup differences: P= 0.002; I2=89.4%). Conclusions Alirocumab and evolocumab appear to be effective in reducing the risk of MACE in subject with diabetes. Moreover, the use of PCSK9 inhibitors provides enhancement of lipid profile of patients with diabetes and dyslipidemia by reducing LDL–c and Lp(a) values." @default.
- W4377019728 created "2023-05-19" @default.
- W4377019728 creator A5016503714 @default.
- W4377019728 creator A5029980638 @default.
- W4377019728 creator A5040457683 @default.
- W4377019728 creator A5064234091 @default.
- W4377019728 date "2023-05-01" @default.
- W4377019728 modified "2023-10-01" @default.
- W4377019728 title "P363 EFFECTS OF ALIROCUMAB AND EVOLOCUMAB ON THE OUTCOMES AND LIPID PROFILE OF DIABETIC PATIENTS: META–ANALYSIS OF RANDOMIZED CONTROLLED TRIALS" @default.
- W4377019728 doi "https://doi.org/10.1093/eurheartjsupp/suad111.436" @default.
- W4377019728 hasPublicationYear "2023" @default.
- W4377019728 type Work @default.
- W4377019728 citedByCount "0" @default.
- W4377019728 crossrefType "journal-article" @default.
- W4377019728 hasAuthorship W4377019728A5016503714 @default.
- W4377019728 hasAuthorship W4377019728A5029980638 @default.
- W4377019728 hasAuthorship W4377019728A5040457683 @default.
- W4377019728 hasAuthorship W4377019728A5064234091 @default.
- W4377019728 hasBestOaLocation W43770197281 @default.
- W4377019728 hasConcept C126322002 @default.
- W4377019728 hasConcept C134018914 @default.
- W4377019728 hasConcept C142724271 @default.
- W4377019728 hasConcept C168563851 @default.
- W4377019728 hasConcept C204787440 @default.
- W4377019728 hasConcept C27081682 @default.
- W4377019728 hasConcept C2778114629 @default.
- W4377019728 hasConcept C2778163477 @default.
- W4377019728 hasConcept C2778270857 @default.
- W4377019728 hasConcept C2780072125 @default.
- W4377019728 hasConcept C2780739214 @default.
- W4377019728 hasConcept C2780745583 @default.
- W4377019728 hasConcept C2780902209 @default.
- W4377019728 hasConcept C2780948078 @default.
- W4377019728 hasConcept C43554185 @default.
- W4377019728 hasConcept C44249647 @default.
- W4377019728 hasConcept C45393284 @default.
- W4377019728 hasConcept C500558357 @default.
- W4377019728 hasConcept C555293320 @default.
- W4377019728 hasConcept C62746215 @default.
- W4377019728 hasConcept C71924100 @default.
- W4377019728 hasConcept C90924648 @default.
- W4377019728 hasConceptScore W4377019728C126322002 @default.
- W4377019728 hasConceptScore W4377019728C134018914 @default.
- W4377019728 hasConceptScore W4377019728C142724271 @default.
- W4377019728 hasConceptScore W4377019728C168563851 @default.
- W4377019728 hasConceptScore W4377019728C204787440 @default.
- W4377019728 hasConceptScore W4377019728C27081682 @default.
- W4377019728 hasConceptScore W4377019728C2778114629 @default.
- W4377019728 hasConceptScore W4377019728C2778163477 @default.
- W4377019728 hasConceptScore W4377019728C2778270857 @default.
- W4377019728 hasConceptScore W4377019728C2780072125 @default.
- W4377019728 hasConceptScore W4377019728C2780739214 @default.
- W4377019728 hasConceptScore W4377019728C2780745583 @default.
- W4377019728 hasConceptScore W4377019728C2780902209 @default.
- W4377019728 hasConceptScore W4377019728C2780948078 @default.
- W4377019728 hasConceptScore W4377019728C43554185 @default.
- W4377019728 hasConceptScore W4377019728C44249647 @default.
- W4377019728 hasConceptScore W4377019728C45393284 @default.
- W4377019728 hasConceptScore W4377019728C500558357 @default.
- W4377019728 hasConceptScore W4377019728C555293320 @default.
- W4377019728 hasConceptScore W4377019728C62746215 @default.
- W4377019728 hasConceptScore W4377019728C71924100 @default.
- W4377019728 hasConceptScore W4377019728C90924648 @default.
- W4377019728 hasIssue "Supplement_D" @default.
- W4377019728 hasLocation W43770197281 @default.
- W4377019728 hasOpenAccess W4377019728 @default.
- W4377019728 hasPrimaryLocation W43770197281 @default.
- W4377019728 hasRelatedWork W161816689 @default.
- W4377019728 hasRelatedWork W2534010974 @default.
- W4377019728 hasRelatedWork W2585426472 @default.
- W4377019728 hasRelatedWork W2620969414 @default.
- W4377019728 hasRelatedWork W2897350816 @default.
- W4377019728 hasRelatedWork W3010198790 @default.
- W4377019728 hasRelatedWork W3140974984 @default.
- W4377019728 hasRelatedWork W4282559726 @default.
- W4377019728 hasRelatedWork W4311093353 @default.
- W4377019728 hasRelatedWork W4360991031 @default.
- W4377019728 hasVolume "25" @default.
- W4377019728 isParatext "false" @default.
- W4377019728 isRetracted "false" @default.
- W4377019728 workType "article" @default.